CMS Promises Further Work On Incentives To Use Non-Opioid Pain Therapies; Finalizes Exparel Carve-Out For Ambulatory Centers

Cystic Fibrosis Treatment Burden Grabs FDA Attention At Oct. 29 Patient Meeting; Reducing Length Of Regimens Is Next Challenge

Prevision Policy Clips | AcelRx’ Dsuvia Approved As Trevena Receives CRL For Oliceridine

FDA Makes A Statement With AcelRx’ Dsuvia Approval; Gottlieb Says Novel Comparative Benefit-Risk Framework For Opioids In Development

Prevision Policy Clips | HHS Drug Pricing Senior Advisor Dan Best Dies

Alkermes’ ALKS-5461 Antidepressant Voted Down By FDA Advisory Committee Based On Lack Of Efficacy; Another Trial Needed

FDA Hemophilia Product Development Meeting Signals Measured Approach To Defining Accelerated Approval Pathway

Prevision Policy Clips | Questions About International Price Indexing? HHS Has Answers – Sort Of

Biopharma Congress Final Agenda: Only Two Weeks Away

Sage’s Brexanolone Poised For Approval As First Post-Partum Depression Therapy, But Only For Clinic/Inpatient Use

The Influencers: Prevision Policy’s List Of Advisory Committee Members With The Most Impact On Drug Reviews

Prevision Policy Clips | 340B Pricing Rule Effective Date Change Clears OMB:

Subscription Pricing Plays Well With Media: “Netflix Model” Makes Topic Sound Fresh, Supportive Of More Content (i.e., More Therapies)

Alkermes Facing Tough Battle At FDA Advisory Committee: Potential For Abuse Of Opioid In Antidepressant Combo May Be Biggest Hurdle

Prevision Policy Clips | Register now for the Biopharma Congress on Nov. 14 in Washington, DC

Payor Hostility Toward OUD Treatments Highlighted By Industry Ahead Of November ICER Meeting

Prevision Policy Clips | Part D Drug Pricing Proposal Goes To OMB

IPI “Target” List: Bulk Of Savings Would Come From Five Part B Therapies – And Two Companies (Genentech And Amgen)

Prevision Policy Clips | Medicare Part B “International Pricing Index” Model

Medicare Part B “International Pricing Index” Model: Shot Across The Bow To Drive Support For Competitive Bidding?

From Goalpost To High Hurdle? FDA Committee Wants “Simpler” CV Safety Standard – But Split Vote Makes FDA’s Next Steps Tough

Facebook-Focused Drug Development: Social Media Verification Among Topics Discussed At FDA PFDD Guidance Workshop

Part B Price International Indexing Demo Floated In HHS Report Ahead Of Drug Pricing Announcement; Is Reviving CAP The Real Agenda?

Prevision Policy Clips | President Trump Drug Pricing Speech Set For 2 PM

OMB’s Grogan Urges Donut Hole Discount Formula Fix By Congress, Calls Payors A “Utility” On The Path To Direct Price Negotiation